Can caffeine consumption during pregnancy cause fetal growth restriction or a low birth weight percentile?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Caffeine During Pregnancy and Fetal Growth Restriction

Yes, caffeine consumption during pregnancy is associated with fetal growth restriction and lower birth weight, even at levels below current recommendations, and pregnant women should limit caffeine intake to less than 200 mg/day (approximately one cup of coffee).

Evidence-Based Recommendations

The European Food Safety Authority recommends limiting caffeine to 200 mg/day during pregnancy 1, while some systematic reviews suggest that even consumption of ≤300 mg/day is generally not associated with adverse reproductive effects 1. However, newer guidelines from multiple countries recommend the more conservative 200 mg/day limit 2.

Dose-Response Relationship

The evidence demonstrates a clear dose-dependent relationship between caffeine and fetal growth:

  • Each 100 mg/day increment in caffeine intake (approximately one cup of coffee) increases the risk of low birth weight by 13% 3
  • Women consuming 50 mg/day (half a cup of coffee) had neonates with lower birth weight (-66 g), smaller arm and thigh circumferences 4
  • Moderate intake (150-349 mg/day) increases low birth weight risk by 38% 3
  • High intake (≥350 mg/day) increases low birth weight risk by 60% 3
  • Women consuming ≥3 coffees daily show statistically significant reductions in birth weight 5

Key Clinical Findings

The most recent high-quality evidence from the NICHD Fetal Growth Studies (2021) demonstrates that caffeine consumption affects multiple neonatal anthropometric measures 4:

  • Women in the highest quartile of plasma caffeine (>659 ng/mL) had neonates with:
    • Lower birth weight (-84.3 g)
    • Reduced length (-0.44 cm)
    • Smaller head circumference (-0.28 cm)
    • Smaller arm and thigh circumferences

Importantly, these effects occurred even at caffeine levels much lower than the recommended 200 mg/day threshold 4.

Mechanism and Metabolism

The association between caffeine and fetal growth restriction is stronger in women with faster caffeine clearance 6, suggesting that caffeine metabolism plays a role. However, a 2023 study using objective metabolomic measures found that when adjusting for objective smoking status, high paraxanthine (caffeine metabolite) levels were not independently associated with adverse outcomes 7, indicating potential confounding by smoking.

Important Caveats

  • Smoking is a major confounder: Studies using objective cotinine measurements show that consistent smoking exposure has much stronger associations with fetal growth restriction (OR = 4.07) than caffeine alone 7
  • The association persists throughout pregnancy, with consumption in all trimesters contributing to risk 6
  • No safe threshold has been definitively established, as even low consumption (50 mg/day) shows measurable effects 4

Practical Clinical Approach

Advise pregnant women to:

  • Limit caffeine to <200 mg/day (one 8-oz cup of coffee or two cups of tea)
  • Consider reducing intake before conception and throughout pregnancy 6
  • Account for all caffeine sources: coffee (primary source at 64%), soft drinks (17%), tea (17%), and energy drinks 1
  • Be aware that decaffeinated options are available and retain beneficial phytonutrients 1

The evidence strongly supports that caffeine restriction during pregnancy reduces the risk of delivering low birth weight infants 3, and the most conservative approach—limiting intake to <200 mg/day—is justified given the dose-response relationship observed even at low levels 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.